Latin America's clinical research reforms are moving decisively from statute to execution, with Brazil and Colombia reaching regulatory and political milestones this week tha
first-in-human · FIH · clinical trial · clinical research · regulatory · ANVISA
Latin America's clinical research reforms are moving decisively from statute to execution, with Brazil and Colombia reaching regulatory and political milestones this week that carry long-term consequences for sponsors, CROs, and research institutions.
Brazil's new clinical trial law delivers its first automatic approvals under the "decurso de prazo" mechanism Colombia elects a new president, reshaping the country's clinical research outlook Mexico continues executing its accelerated regulatory modernization agenda ANVISA expands its broader regulatory modernization program beyond clinical trials Global CRO expansion intensifies competition for early-phase studies Argentina continues building its clinical research position through reform and investment
Take a closer look at each development. 👇
For the first time since Lei 14.874/2024 took effect, ANVISA has allowed eight clinical research petitions to move forward automatically after the agency exceeded its statutory review deadline. The approvals were published through Resolution RE No. 2.413 and cover protocol amendments, investigational product modifications, and clinical development dossiers involving major sponsors including Janssen and Roche.
The decision marks a genuine operational milestone in Brazil's regulatory modernization. Rather than waiting indefinitely for written authorization, eligible studies can now proceed under the "decurso de prazo" mechanism established by Article 58 of the new law. The development offers early evidence that Brazil's new framework is beginning to deliver the predictability it was designed to provide.
Why it matters: Sponsors evaluating Brazil for pivotal or early-phase programs now have a concrete signal that the statutory timelines built into Lei 14.874/2024 are enforceable in practice, not just in law.
Abelardo de la Espriella has won Colombia's presidential runoff by one of the narrowest margins in the country's history, although the result remains subject to ongoing electoral scrutiny. The election represents more than a political transition. During the campaign, de la Espriella outlined plans to restructure parts of Colombia's healthcare system, proposals that could ultimately influence PL 191, INVIMA modernization, and the broader regulatory environment for clinical research.
While no immediate policy changes are expected before the August 7 inauguration, the result introduces a new chapter for one of Latin America's most important clinical research markets. Sponsors with active or planned Colombian programs should watch the first hundred days closely.
What to focus on: PL 191 status, any signals on INVIMA leadership continuity, and the trajectory of the country's Registro Sanitario reform pipeline through Q3.
Mexico continues advancing one of the region's most ambitious regulatory modernization efforts. Recent updates from COFEPRIS and AMIIF indicate that response times have already been reduced substantially, while implementation of the agency's new reliance framework and digital platform continues ahead of its July launch. Combined with the 30-day clinical trial authorization target announced earlier this year, these operational changes are positioning Mexico as an increasingly competitive destination for early-stage clinical research.
Bottom line: For sponsors previously defaulting to Panama or Chile for LATAM speed, Mexico's evolving reliance framework and 30-day target warrant a fresh look — particularly for programs where the eventual commercial market is North America.
Beyond clinical trial approvals, ANVISA continues broadening its modernization agenda. Recent actions include new technical guidance on biosimilar interchangeability and the creation of an expert working group to further evaluate the safety profile of the Butantan-DV dengue vaccine. While these initiatives extend beyond clinical trials themselves, they reflect a broader regulatory strategy focused on strengthening scientific oversight and modernizing Brazil's health regulatory framework.
bioaccess® is the specialized CRO built exclusively for first-in-human and early-feasibility clinical trials in Latin America. Sponsors partner with us to:
Execute FIH and EFS programs 40% faster than U.S. sites, at 30% lower cost Access ICH-GCP-trained monitoring, ISO 14155 quality systems, and 21 CFR Part 11 EDC across 10 LATAM countries Convert an OUS pivotal from a fundraising abstraction into a submission-ready dataset for FDA, EMA, or PMDA
Schedule your first-in-human trial consultation at bioaccessla.com/roadmap.
Avance Clinical has announced an expansion into Asia-Pacific and mainland China, extending its global footprint ahead of BIO International Convention 2026. Although the announcement is not LATAM-specific, it reflects a broader trend toward international CRO expansion and increasing competition for early-phase clinical programs. As global providers continue expanding geographically, regional CROs may increasingly differentiate themselves through local regulatory expertise, investigator relationships, and operational execution.
Argentina continues strengthening its profile as a destination for clinical research through a combination of regulatory modernization and long-term investment. Recent developments, including ANMAT's continued international engagement and growing investment commitments, highlight the country's effort to build a more competitive environment for MedTech and Biopharma clinical development. As implementation of Argentina's 62-day authorization framework continues, the country's broader strategy increasingly combines regulatory reform with sustained investment in research infrastructure.
Brazil's Lei 14.874/2024 is now producing real automatic approvals through Article 58's "decurso de prazo" mechanism, not just theoretical timelines. Colombia's presidential election introduces meaningful uncertainty around PL 191, INVIMA modernization, and healthcare system restructuring through Q3 and beyond. Mexico's reliance framework and 30-day clinical trial target are compressing timelines and shifting competitive positioning for FIH and pivotal work. ANVISA's modernization agenda extends beyond clinical trials into biosimilars and vaccine safety, signaling a broader shift in scientific oversight. Global CRO consolidation intensifies competition for early-phase studies, elevating the differentiation value of regional expertise. Argentina's 62-day authorization framework, paired with sustained investment, continues to position the country as a serious contender for LATAM clinical work.
← All Global Trial Accelerators editions · Contact bioaccess®